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Vascular permeability is frequently associated with
inflammation and is triggered by a cohort of secreted
permeability factors such as vascular endothelial
growth factor (VEGF). Here, we show that the physi-
ological vascular permeability that precedes implan-
tation is directly controlled by progesterone receptor
(PR) and is independent of VEGF. Global or endo-
thelial-specific deletion of PR blocks physiological
vascular permeability in the uterus, whereas misex-
pression of PR in the endothelium of other organs
results in ectopic vascular leakage. Integration of
an endothelial genome-wide transcriptional profile
with chromatin immunoprecipitation sequencing
revealed that PR induces an NR4A1 (Nur77/TR3)-
dependent transcriptional program that broadly
regulates vascular permeability in response to pro-
gesterone. Silencing of NR4A1 blocks PR-mediated
permeability responses, indicating a direct link be-
tween PR and NR4A1. This program triggers concur-
rent suppression of several junctional proteins and
leads to an effective, timely, and venous-specific
regulation of vascular barrier function that is critical
for embryo implantation.INTRODUCTION
The endothelium consists of a highly specialized cell population
that lines the inner layer of the vascular tree. The particular loca-
tion of blood vessels imposes functional demands, intrinsic
to each organ, that exceed its well-accepted role as a barrier
and nonthrombogenic surface. To accommodate organ-specificfunctions, endothelial cells differ in regard to structure, adhesion
molecules, metabolic properties, antigenic expression, and cell-
surface determinants (Atkins et al., 2011; Chappell and Bautch,
2010; Regan and Aird, 2012). However, we are significantly
behind in our understanding of how unique vascular functions
are developed and maintained to confer specific properties to
individual tissues.
In the endometrium, cycles of vascular repair and angiogen-
esis occur in addition to the underlying organ-specific require-
ments. The repair and regrowth of the endometrium is driven
by the sequential and tightly controlled interplay of steroid hor-
mones. In particular, endometrial angiogenesis appears to be
regulated by 17-b estradiol (E2), likely through the ER-b receptor,
as indicated by its high expression in primate endometrial
vascular and perivascular cells (Arnal et al., 2010; Kim and
Bender, 2009). Consistent with this prediction, low concentra-
tions of E2 induce proliferative andmigratory responses in endo-
thelial cells (Bernelot Moens et al., 2012). More importantly, ER-b
knockout mice acquire abnormal vascular function and hyper-
tension associated with endothelial dysfunction and impaired
angiogenesis (Iafrati et al., 1997; Zhu et al., 2002). Furthermore,
E2 regulates expression of vascular endothelial growth factor
(VEGF) and has been shown to promote vascular expansion in
the endometrium of primates (Hyder et al., 1996; Sugino et al.,
2002).
A unique feature of endometrial vessels is cyclic alterations in
vascular permeability. These events result in the recurrent for-
mation of a physiological edema during the second half of the
endometrial cycle (secretory phase), a time when progesterone
(P4) levels peak (Strauss and Barbieri, 2009). Increased perme-
ability alters the functional endometrium and makes it receptive
for embryonic implantation. As part of the decidual response,
changes in the degree of permeability parallel the ovarian cycle
and are extremely pronounced during pregnancy (Gellersen
et al., 2007). The leakage of blood-borne proteins to the intersti-
tium is critical to support the highly metabolic trophoblastic cellsCell 156, 549–562, January 30, 2014 ª2014 Elsevier Inc. 549
and to ensure the survival of the blastocyst. Interestingly, ani-
mals that lack PR are unable to mount a decidual response
(Lydon et al., 1996, 1995), placing PR as the upstream coordi-
nator of the cellular and molecular changes that regulate
decidualization, including alterations in the stroma, matrix, and
vasculature (Large and DeMayo, 2012).
In this study, we provide evidence that PR is required within
the endothelial compartment to mediate physiological vascular
permeability. The resulting edema is independent of VEGF and
instead is triggered by PR-dependent activation of nuclear
receptor subfamily, group A, member 1 (NR4A1). Ultimately,
through this mechanism, PR is able to selectively target the
endometrial vasculature in a coordinated and sustained perme-
ability response.
RESULTS
Complete Deletion of PR Leads to Reduced
Physiological Vascular Permeability
To dissect the biological function of PR in the endometrial vascu-
lature, we first examined mice with global deletion of PR (PRKO)
and littermate controls. Exposure of controlmice toP4 resulted in
uterine hyperplasia (Figure 1A) with a concurrent weight increase
of 2.5-fold (Figure 1F). In contrast, PRKO uteri failed to mount
an equally significant response (Figures 1A and 1F). Sections
stained with a collagen IV antibody or perfused intravascularly
with Lycopersicon esculentum lectin showed equivalent vascular
density between groups regardless of whether they were treated
with vehicle or hormones (Figures 1B–1D). Histological analysis
also revealed a similar overall structure between control and
PRKO mice (Figure S1A available online); however, expression
of mucin1, an epithelial glycoprotein, and several proteoglycans
were decreased in PRKO uteri (Figure S1B). These differences
were indicative of deficiencies in the differentiation of the uterus.
Because uterine hyperplasia could be due to increased intersti-
tial fluid,we assessedwhether the changes in uterineweightwere
due to an accumulation of plasma proteins extravasated from the
vascular compartment. Hormone (E2 andP4) treatment of control
mice resulted in a 3.8-fold increase in Evans blue content. This
was in contrast to PRKO mice, which showed no differences
in uterine permeability (Figure 1G). Furthermore, inhibition of PR
bymifepristone (RU486)blocked theeffectofP4onuterineweight
(Figure 1H) and Evans blue extravasation (Figure 1I), whereas
inhibitors of other permeability mediators (VEGFR2 [SU11248]
and bradykinin [HOE 140]) had no effect. These results suggest
that P4, through PR, regulates uterine vascular permeability inde-
pendently of classical pathological permeability mediators.
PR Expression in the Vasculature Is Restricted to
Endothelial Cells of the Veins and Lymphatics of the
Uterus and Ovary
Because the endothelium is largely responsible for regulation of
vascular permeability, we first evaluated whether the effect of P4
on barrier function is direct and occurs through PR expression in
endothelial cells. The presence of PR in the vasculature has been
the subject of debate, with a number of publications supporting
(Krikun et al., 2005; Maybin and Duncan, 2004; Va´zquez et al.,
1999) or negating (Ismail et al., 2002; Perrot-Applanat et al.,550 Cell 156, 549–562, January 30, 2014 ª2014 Elsevier Inc.1995) its expression in endothelial and smooth muscle cells.
Using PRLacZ mice (Figure S2), which report both PRA and
PRB promoter activation, we found that indeed endothelial cells
were b-gal+ (Figure 2A). Interestingly, PR+ endothelial cells were
restricted to venules and lymphatics of the uterus and ovary, but
absent from arterioles (Figures 2A and S2G). Smooth muscle
cells and/or pericytes were also positive; however, b-gal reac-
tivity was equivalent in both arterioles and venules (Figure 2A).
Under physiological conditions, PR promoter activity was not
detected in the vascular beds of any other organs (Figure S2H),
revealing an exclusive organ specificity for PR to vessels of the
uterus and ovary.
Expression of PR in the vasculature was confirmed at the
protein level by immunohistochemistry. Similar to findings from
PRLacZ reporter mice, endothelial cells of veins and lymphatic
vessels were positive for both PECAM-1 and PR, whereas arte-
rial endothelial cells lacked PR expression (Figure 2B). Expres-
sion of PR in human endometrium was also exclusive to the
endothelium of veins (Figure 2C).
It should be emphasized that PRexpression in the endothelium
is not constitutive. On average, at any given time, PR+endothelial
cells represent 22.7% (32.5% following hormone treatment) of
uterine venous and 21% of lymphatic (24% following hormone
treatment) endothelial cells per vessel cross-section (Figure 2D).
Additionally, on average 30%–40% of uterine vessels express at
least one b-gal+ endothelial cell (Figure 2E). Upon pregnancy,
transcripts for PR increase by 4.5-fold in the uterus (Figure 2F)
and by 3.2-fold in fluorescence-activated cell sorting (FACS)-
sorted endothelial cells (Figure 2G). Furthermore, the frequency
of PR+ endothelial cells is also increased specifically in veins at
day 5.5 of gestation (Figures 2H and 2I).
PR Signaling in the Endothelium Promotes Vascular
Permeability In Vivo
To determine whether the effect on vascular permeability was
due to PR activity in endothelial cells, we evaluated cell-specific
deletion of PR (PRECKOmice) (Figures S3A and S3B). Cre expres-
sion in the uterus and ovary was completely restricted to the
endothelium of the vasculature, as determined by b-gal
positivity using R26R reporter mice (Figure S3C). The effect of
recombination was highly penetrant, as demonstrated by PR
deletion in FACS-sorted endothelial cells (Figures S2E and S2F).
Using the Miles assay, we examined control and PRECKO mice
for changes in permeability following hormone treatment
(E2+P4). PRECKO uteri had significantly reduced Evans blue con-
tent, yet the duodenum, which lacks PR expression, did not
exhibit changes in permeability (Figures 3A and 3B). These re-
sults were confirmed bymeasurements of albumin in the intersti-
tial uterine tissue (Figures 3C and 3D).Whereas hormone-treated
control animals exhibited a 4.79-fold increase in albumin levels,
PRECKO mice, albeit responsive, showed only a 1.9-fold increase
of no statistical significance (Figure 3C). Albumin levels in PRKO
mice were not affected by treatment. It should be stressed that
PRKO mice showed greatly reduced levels of proteoglycans
(Figure S1B), which have been shown to be important for water
retention and likely contribute to explain this effect. As expected,
pregnancy increased albumin extravasation in control mice, yet
this effect was significantly reduced in PRECKO mice (Figure 3D).
Figure 1. Reduced Physiological Permeability in the Uterus following Global PR Deletion
(A) Effect of hormones (E2+P4) on control (wild-type) and PRKO uteri. Scale bar, 3 mm.
(B) Collagen IV immunostaining (green) detects basement membrane of glands (arrows) and blood vessels (arrowheads). Scale bar, 100 mm.
(C) Uteri following intravascular perfusion with fluorescein isothiocyanate-conjugated Lycopersicum esculentum lectin. Scale bar, 1 mm.
(D) Vessel number/0.1 mm2 in control and PRKO mice.
(E) Uterine cell density/mm2 in control and PRKO mice.
(F) Uterine wet weight in control and PRKO mice.
(G) Uterine Evans blue content measured by the Miles assay.
(H) Uterine wet weight following concurrent treatment of E2+P4 with inhibitors of VEGFR2 (SU11248), bradykinin (HOE140), and PR (RU486).
(I) Quantification of Evans blue after the conditions listed in (H).
In all panels, error bars show ±SEM. **p < 0.01, ****p < 0.0001. n = 3–5. See also Figure S1 and Table S1.
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Figure 2. PR Expression in the Murine Vasculature
(A) b-gal positivity in transverse uterine sections from PRLacZ+/ and PRLacZ+/+ mice treated with oil, E2 and P4, or pregnant mare serum gonadotropin (PMSG)/
human chorionic gonadotropin (HCG). Arrowheads, endothelial cells; arrows, smooth muscle cells; A, arteries; V, veins. Nuclear Fast Red was used as a
counterstain.
(B and C) Immunofluorescence of murine (B) and human (C) uterine sections stained for PECAM-1 (red) and PR (green). Nuclei were visualized using DAPI (blue).
Arrowheads, endothelial cells; arrows, smooth muscle cells. Insets are higher-magnification images of PR+ endothelial cells.
(D) Percentage of b-gal+ endothelial cells per vessel cross-section from PRLacZ+/ mice (n = 3).
(E) Percentage of vessels in the uterus that contain at least one b-gal+ endothelial cell per cross-section (n = 3).
(F) Total PR mRNA levels in the uterus from virgin, ovarectomized (OVX), and pregnant (E5.5) mice.
(G) PR mRNA levels from isolated uterine endothelial cells from the same mice listed in (F).
(H) PR protein expression in the endothelium of virgin and pregnant (E5.5) mice. Arrows, PR+ endothelial cells; A, arteries; V, veins.
(I) Percentage of PR+ endothelial cells per vessel cross-section from virgin and pregnant uteri (E5.5; n = 3).
(J) Percentage of vessels from virgin and pregnant uteri that contain at least one PR+ endothelial cell per cross-section (n = 3).
In all panels, error bars show ±SEM. Scale bar, 25 mm. *p < 0.05, **p < 0.01, ***p < 0.001 ****p < 0.0001. See also Figure S2.
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Figure 3. Reduced Vascular Permeability upon Conditional Deletion of PR in the Endothelial Compartment
(A) Evans blue extravasation in control (PRCE; Cre) and PRECKO mice. Scale bar, 7 mm.
(B) Evans blue content in uterus and intestine following hormone stimulation (n = 7–8).
(C) Uterine albumin concentrations from control, PRKO, and PRECKO animals following vehicle or E2+P4 treatment.
(D) Uterine albumin concentrations from ovarectomized (OVX) control and PRECKO animals following vehicle and E2+P4. Early pregnancy (gestational day 3) was
also examined.
(E) Whole-mount images depicting implantation sites (arrows) in control and PRECKO mice following embryo transfer. Scale bar, 5 mm.
(F) Quantification of implantation sites at gestational day 9 following embryo transfer in control and PRECKO mice.
(G) Schematic depicting treatment of pregnant control females (gestational days 3, 7, and 12) with vehicle, RU486 (PR antagonist), and sunitinib (VEGFR2
antagonist). Black arrows represent time of injection. Implantation sites were quantified at E15 and are represented in the bar graphs below.
(H) Ricinus communis agglutinin I (green) and Lycopersicon esculentum (red) staining of uteri from control and PRECKO animals following E2+P4. Arrows indicate
sites of permeability (green). L, lymphatic. (a and b) Enlarged images of boxes in (H). Scale bar, 50 mm.
(I) Immunohistochemistry of pVE-cadherin (red) and PR (green). DAPI (blue) shows nuclei. Higher magnification in box on right. Arrowheads, pVE-cadherin
expression; arrows, lack of pVE-cadherin; star, PR+ cell; asterisk, PR cell; E, endometrium; M, myometrium. Scale bar, 20 mm.
(J) Western blot for pVE-cadherin protein levels in uteri of virgin control and PRECKO mice. Tubulin was used as the loading control.
(K) Western blot for total pVE-cadherin protein levels from pregnant uteri (gestational days 5, 7, and 12) of control and PRECKO mice. Tubulin was used as the
loading control.
In all panels, error bars show ±SEM. **p < 0.01, ****p < 0.0001. See also Figure S3.
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To explore the biological relevance of these findings, we
performed implantation assays in control and PRECKO mice (Fig-
ure 3E). The results revealed a 43% reduction in the number of
implantation sites in PRECKO mice compared with controls
(Figure 3F). Because PR has been shown to regulate VEGF, we
sought to evaluate the effect of blocking VEGFR2 during pre-
and postimplantation times. P4 blockade, as anticipated, pre-
vented implantation at all gestational time points examined,
whereas inhibition of VEGF signaling only impacted embryo
viabilitywhen administered at postimplantation times (Figure 3G).
The absence of PR in the endothelium did not change vascular
density (FigureS3D),butdidaffect vascular function.Veinsspecif-
ically failed to exhibit signsof vascular leakage, as shownby injec-
tion with Ricinus communis agglutinin I (RCAI) lectin (Figure 3H).
Phosphorylation of VE-cadherin, a molecular readout of barrier
instability, was present at the interface of PR+ cells, while PR
cells showed reduced pVE-cadherin (Figure 3I). This finding was
also confirmed by total protein lysates from uteri of control and
PRECKOmice (Figure3J). Finally,whereaspermeability associated
with pregnancy resulted in an increase in VE-cadherin phosphor-
ylation, this effect was muted in PRECKO mice (Figure 3K).
We further scrutinized the function of PR in endothelial cells by
ectopic expression using a transgenicmousemodel (Figure S3G;
Table S1). The relative levels of transgenic PR protein confirmed
that the lung was by far the site of highest expression, followed
by the intestine, whereas the kidney, uterus, and heart showed
a complete absence of PR (Figures S3H–S3J). Consistent with
the lack of transgene expression in uteri, P4 treatment resulted
in equivalent extravasation of Evans blue (Figure S3K). In
contrast, vascular permeability in PRTg lungs was 5.3-fold
greater than baseline, and leakage in the duodenum increased
by 1.6-fold (Figures S3L and S3M). Immunohistochemical anal-
ysis of RCAI-injected mice revealed barrier dysfunction in the
lung following hormone treatment and provided additional sup-
port to the Miles assay (Figure S3N).
PR Activation in Endothelial Cells Results in
Interendothelial Gaps and Decreased Endothelial
Monolayer Resistance
Having established that endothelial PR promoted vascular
permeability in vivo, we returned to in vitro settings to gainmech-
anistic insights. First, we examined human endometrial endothe-
lial cells (HEECs) that express endogenous PR. Similar to the
findings in murine and human endometrial sections, the pres-
ence of PR was heterogeneous (Figure 4A), which provided an
important advantage because it allowed for concurrent assess-
ment of PR cells in the same culture. To determine the effect of
P4 on junctional complexes, we used b-catenin immunolocaliza-
tion. Cell-cell integrity was stable in nontreated (Figure 4Aa) and
vehicle-treated (Figure 4Ab) HEECs. However, P4 treatment
induced translocation of b-catenin away from adherens junc-
tions and resulted in the formation of intercellular gaps only in
HEECs expressing PR (orange nuclei), while cells that lacked
PR remained bound (Figure 4Ac, bracket).
A more comprehensive evaluation of the effect of PR on
junctional proteins was performed in human umbilical vein endo-
thelial cells (HUVECs) infected with a PR lentivirus (Figures 4B
and 4C). Exposure to P4 resulted in clear loss of PECAM-1 (Fig-554 Cell 156, 549–562, January 30, 2014 ª2014 Elsevier Inc.ure 4B), VE-cadherin (Figure S4A), and b-catenin cell-surface
expression (Figure 4C). Biochemically, b-catenin was found to
translocate from the cell membrane to the cytosol and nucleus
upon treatment with P4 (Figures 4C and 4D). These effects
were absent in HUVECs that lacked PR whether in the presence
or absence of P4 (Figure S4B).
To evaluate the progression of junctional breakdown in real
time, we used electrical cell-substrate impedance sensing
(ECIS) on endothelial monolayers (Figure 4E). Following P4 treat-
ment, human dermal endothelial cells (HDECs) overexpressing
PR exhibited a progressive decrease in resistance, with initial
barrier destabilization occurring between 4 and 8 hr after P4
addition (Figure 4F). At 17 hr, the reduction in barrier resistance
was equivalent to that induced by thrombin (at 30 min), a land-
mark control for these types of experiments. Notably, in contrast
to the short effect mediated by thrombin, P4 exposure resulted in
persistent and continuous barrier breakdown.
To confirm that the changes in resistance were due to cellular
gaps, we visualized b-catenin expression in the same cells
measured by ECIS. As expected, cells that exhibited a decrease
in electrical resistance also displayed discontinuous cell-cell
adhesion (Figure S4C). Furthermore, the effects on barrier integ-
rity were found to be dose dependent (Figure 4G) and ceased
after removal of P4 (at physiological levels) (Figure 4H). Surpris-
ingly, inhibition of classical permeability signaling molecules,
including Src (Figure S4D), PI3K (Figure S4E), ROCK (Fig-
ure S4G), and VEGFR2 (Figure S4H), or taxol-mediated micro-
tubule stabilization (Figure S4F) did not inhibit P4-induced
permeability, suggesting that a novel mechanismmay act down-
stream of PR.
Endothelial PR Signaling Alters Junctional Protein
Expression
Using next-generation RNA sequencing (RNA-seq), we explored
the notion that PR signaling may transcriptionally alter the
expression of endothelial junctional proteins. Following 4 hr of
P4 treatment, we compared the fold change of several genes
known to regulate vascular permeability (Figure 5A). As ex-
pected, many of the genes that encode proteins important for
junctional stability, such as VE-cadherin (CDH5), VE-PTP
(PTPRB), PECAM-1, and claudin-5 (CLDN5), were reduced
upon P4 exposure. Quantitative PCR (qPCR) analysis of VE-cad-
herin and claudin-5 confirmed the reduction noted by RNA-seq
(Figure 5B). Western blot analysis demonstrated a significant
reduction in junctional protein levels starting at 16 hr after treat-
ment (Figures 5C and 5D), supporting the kinetics revealed by
HUVEC immunofluorescence (Figure S4A). b-catenin levels re-
mained unchanged at both the RNA and protein levels, which
correlated with protein translocation rather than reduction. Other
endothelial-matrix associated proteins, including focal adhesion
kinase (FAK) and b1-integrin, were not affected by P4 addition
(Figure S5A).
To determine whether transcriptional activation and subse-
quent protein synthesis were required for P4-mediated perme-
ability, HUVECs were treated with inhibitors of transcription
and translation (Figures 5E and 5F). Both inhibitors completely
blocked the decrease in monolayer resistance observed upon
P4 treatment, confirming the requirement for transcriptional
Figure 4. PR Activation in Endothelial Cells Results in Barrier Disruption
(A) Immunohistochemistry of HEEC for PR (orange) and b-catenin (green, arrows). (a) low magnification, (b) high magnification treated with vehicle, and (c) high
magnification treated with P4. PR cell islands are indicated by the bracket. Scale bar, 100 mm.
(B) PECAM (white) in HUVECs infected with a PR lentivirus (GFP, green) following 24 hr of P4 treatment (100 nM). DAPI (blue) shows nuclei. Arrows indicate
junctional disruption. Arrowheads show the presence of PECAM in PR cells. Scale bar, 10 mm.
(C) b-catenin (white) in HUVECs infected with a PR lentivirus (green, GFP) following 8 hr of P4 treatment (100 nM). DAPI (blue) shows nuclei. Arrowheads show
translocation of b-catenin from the cell membrane to cytosol. Scale bar, 10 mm.
(D) Presence of b-catenin in subcellular fractions from HUVECs infected with GFP-control or hPR lentivirus. Cells were treated with or without P4 for 24 hr as
indicated. C, cytosol; N, nuclear; M, membrane; TL, total lysate. Numbers below indicate quantification of western blot.
(E) Diagram depicting ECIS.
(F) Monolayer resistance of HDECs following infection with a PR adenovirus and b-gal control construct. Thrombin was used as positive control.
(G) HDEC monolayer resistance following treatment with increasing concentrations of P4 as indicated.
(H) Evaluation of HDEC monolayer resistance after removal of P4 from the media. Black arrow, P4 addition; gray arrow, P4 removal. n = 3–5.
See also Figure S4.regulation and de novo protein synthesis downstream of PR
signaling.
PR Binds Directly to the NR4A1 Promoter and Regulates
NR4A1 Gene Expression
A concrete elucidation of PR’s mechanism of action required
us to ascertain the cohort of PR-regulated genes in the endo-
thelium and identify within this cohort the intermediateeffector(s). For this purpose, we obtained a global readout
of PR-binding sites in the HUVEC genome using chromatin
immunoprecipitation sequencing (ChIP-seq). In the absence
of ligand (PR only), we resolved 525 PR-binding sites, whereas
activation of the receptor by P4 (PR+P4) resulted in a much
higher number of PR-binding sites (9,906), 396 of which over-
lapped with PR only peaks. To identify genes that might be
regulated by PR, we next associated PR+P4-binding sitesCell 156, 549–562, January 30, 2014 ª2014 Elsevier Inc. 555
Figure 5. PRActivation Leads to Changes in
Expression of Junctional Proteins
(A) Heatmap representing the relative expres-
sion and fold change of genes known to regulate
vascular permeability in PR versus PR+P4
HUVECS at 4 hr.
(B) qPCR of VE-cadherin (CDH5) and claudin-5
(CLDN5) expression following P4 treatment of
noninfected (NI), GFP-infected (GFP), and PR-
infected (hPR) HUVECs. n = 3. GFP-infected
HUVECs were used as a control for infection.
(C) Western blot analysis of total protein levels
from GFP control or PR-infected HUVECs
following P4 treatment. Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH)/b-actin served as
loading controls. Blots are representative of three
independent experiments.
(D) Densitometry of VE-cadherin, claudin-5, and
PECAM-1 protein levels following P4 treatment.
n = 3.
(E and F) Evaluation of HUVEC monolayer resis-
tance following treatment with cycloheximide
(CHX, 10 mg/ml), actinomycin D (ACD, 10 mg/ml), or
P4 and vehicle as indicated.
Error bars show ±SEM. *p < 0.05, **p < 0.01, ***p <
0.001. See also Figure S5.(9,906) with nearby genes within a 50 kb range from transcrip-
tional start sites, and identified 3,886 predicted bound genes
following P4 treatment (Figure 6A).
To find direct PR target genes whose expression was
affected in response to P4, it was necessary to combine the
ChIP-seq and RNA-seq data sets (Figure 6B). RNA-seq anal-
ysis of HUVECs yielded 406 upregulated and 431 downregu-
lated genes with a p value less than 0.01 (Figure 6B). These
genes were then intersected with the list of 3,886 genes pre-
dicted to be regulated by the PR-binding sites obtained from
ChIP-seq evaluation. This analysis showed that 93 (23%) of
activated and 214 (49%) of repressed genes are likely direct
targets of PR in endothelium. To identify which biological
processes might be regulated by PR, we subjected directly
activated (Figure 6C) and repressed (Table S2) gene lists to556 Cell 156, 549–562, January 30, 2014 ª2014 Elsevier Inc.the DAVID Bioinformatics Database for
Gene Ontology (GO) (Huang et al.,
2009). Interestingly, ‘‘transcription’’ was
the top term associated with directly
upregulated genes (Figure 6C). Since
P4-mediated permeability requires de
novo protein synthesis, we further
focused on the 28 transcription factors
that are directly upregulated by PR by
examining fold upregulation after P4
treatment (Figure 6D).
Notably, only one of these transcription
factors, NR4A1, has been previously
implicated in vascular permeability
(Zhao et al., 2011). Two distinct PR-bind-
ing peaks were found between 10 and 25
kb upstream of the NR4A1 start site inPR+P4 samples, but not in respective controls (Figure 6E).
qPCR confirmed significant NR4A1 upregulation as early as
1 hr after P4 addition (Figure 6F). Interestingly, NR4A1 expres-
sion continued to increase and sustained elevated levels as
long as 24 hr after P4 stimulation. To further validate direct PR
binding at theNR4A1 locus, we analyzed intervals that putatively
contained PR binding, along with a negative control region, by
ChIP-qPCR (Figure 6G). PR binding was significantly enriched
at both regions corresponding to ChIP-seq peaks as compared
with control samples (Figure 6G).
NR4A1 Is Required for Progesterone-Mediated
Endothelial Permeability
Endothelial barrier stability was enhanced when NR4A1 was
knocked down using small interfering RNA (siRNA; Figures 7A
Figure 6. NR4A1 Is a Direct Target of PR
(A) Venn diagram of PR binding peaks betweenHUVECs treatedwith (red) or without (blue) P4 for 1h. Predicted gene numbers based on analysis of binding peaks
within 50kb of the transcriptional start site.
(B) Venn Diagram representing the overlap between genes predicted to be regulated by PR by ChIP-seq and genes with a p value less than 0.01 as determined by
RNA-seq.
(C) Top gene ontology terms from activated genes bound by PR as predicted by DAVID.
(D) Heat map depicting expression and fold change of the 28 transcription factors that were in the top gene ontology pathway from (C).
(E) Depiction of two PR binding peaks upstream of the NR4A1 gene in the presence of P4. Neg. control = noninfected (NI) HUVECs.
(F) qPCR analysis of NR4A1 expression following P4 treatment of noninfected (NI), GFP infected (GFP) and PR infected (hPR). n = 3.
(G) ChIP-qPCR analysis of both NR4A1 binding peaks following P4 treatment. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
In all panels, error bars show ±SEM. See also Figure S6 and Table S2.
Cell 156, 549–562, January 30, 2014 ª2014 Elsevier Inc. 557
Figure 7. Knockdown of NR4A1 Inhibits Progesterone-Mediated Permeability
(A) qPCR analysis of NR4A1 following transfection of HUVECs with either nontargeting (NT) or NR4A1 siRNA. n = 3.
(B) Baseline HUVEC monolayer resistance following NR4A1 knockdown.
(C) HUVEC monolayer resistance after transfection with NR4A1 or NT siRNA in the presence of P4.
(D) HUVEC monolayer resistance following adenoviral infection with a NR4A family dominant-negative (NR4A DN) and control (GFP) in the presence of P4.
(E) HUVECs expressing PR (GFP, green) and transfected with either NT or NR4A1 siRNA were treated with P4 for 24 hr. PECAM, VE-cadherin, and b-catenin
(white) were used to visualize junctions. DAPI (blue) denotes nuclei. Arrowheads indicate a reduction in junctional proteins. Arrows show expanded junctional
area. Scale bar, 50 mm.
(F) Junctional proteins fromGFP or PR infected HUVECs following transfection with either NT orNR4A1 siRNA followed by P4 treatment. GAPDHwas the loading
control.
(legend continued on next page)
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and 7B). Although P4 increased permeability in PR-expressing
HUVECs, this effect was largely blocked by the knockdown of
NR4A1 (Figure 7C). To further scrutinize these findings, we
infected HUVECs with an adenovirus containing a dominant-
negative construct (NR4A DN) for all NR4A family members
(Pei et al., 2006). Similar to NR4A1 knockdown, overexpression
of the NR4A DN inhibited P4-mediated permeability (Figure 7D).
Immunocytochemistry further supported the concept that
NR4A1 acts downstream of PR to regulate barrier breakdown
in endothelial cells. Although HUVECS treated with nontar-
geting siRNA showed reduced VE-cadherin and PECAM-1
levels as well as b-catenin relocalization, these effects were
blocked in cells with NR4A1 knocked down (Figure 7E).
Interestingly, knockdown of NR4A1 led to an increase in mem-
brane expression of all three junctional proteins, consistent
with the increase in basal resistance revealed by ECIS. Protein
analysis further demonstrated the reduction of claudin-5,
PECAM-1, and VE-cadherin in HUVECs transfected with
nontargeting siRNA (Figures 7F and S7A–S7C). PR levels
between nontargeting and knockdown cells were similar, ruling
out possible changes in PR expression as the determinant of
this effect.
Since PR also directly stimulates NR4A2 expression (Figures
S6A–S6C), we examined the effect of NR4A2 reduction on
permeability (Figure S6D). Knockdown of NR4A2 by three inde-
pendent siRNA constructs did not inhibit P4-mediated perme-
ability, demonstrating a unique role for NR4A1 in the regulation
of the endothelial barrier (Figure S6E).
We examined the in vivo expression of NR4A1 using a GFP
reporter mouse (Table S1). GFP, as a readout of NR4A1, was
largely restricted to the vasculature, particularly endothelial cells
(Figure 7G). Unlike PR expression,NR4A1was seen in both veins
and arteries, but colocalization of PR and NR4A1 was frequently
found in veins (Figure 7H). Using qPCR of whole uteri, we found
that NR4A1 expression was responsive to P4 stimulation,
as mRNA levels were 3.8-fold higher following treatment. This
same increase was not seen in PRECKO mice, suggesting that
PR signaling in the endothelium enhances NR4A1 expression
(Figure 7I). To determine whether loss of NR4A1 had biological
implications for uterine vascular permeability, we examined
Evans blue extravasation following hormone stimulation in
NR4A1 null mice. Similar to findings in PRECKOmice, a significant
reduction in Evans blue content was seen in the uterus, but not
the intestine, of NR4A1 KO mice (Figure 7J).
The ability ofNR4A1 to directly control expression of junctional
proteins was also tested in gain-of-function experiments. Over-
expression of NR4A1 resulted in a marked reduction in VE-cad-
herin, claudin-5, andPECAM-1 in the absence of P4 (Figure S7E).
Furthermore, expression of NR4A1 alone increased monolayer
resistance as determined by ECIS (Figure S7D), providing addi-
tional functional validation. These results indicate that NR4A1 is(G) NR4A1 (GFP, green) localization in the vascular endothelium in vivo (PECAM
(H) PR (blue) andNR4A1 (GFP, green) colocalization in uterine vasculature (PECAM
(I) qPCR of NR4A1 from the uteri of virgin, ovariectomized (OVX), and PRECKO m
(J) Evans blue content from the uterus and intestine following hormone stimulatio
bars show ±SEM.
See also Figure S7.required and acts downstream of PR to mediate endothelial spe-
cific vascular permeability.
DISCUSSION
The sequential and highly coordinated actions of the steroid hor-
mones E2 and P4 are known to regulate epithelial and stromal
functions in the endometrium (Das et al., 2009; Gellersen et al.,
2007; Wetendorf and DeMayo, 2012). Changes imposed by
these steroid hormones prepare the endometrium for implanta-
tion and continue to be essential during the subsequent postim-
plantation phases to ensure a successful pregnancy (Franco
et al., 2012; Wetendorf and DeMayo, 2012). Whereas much is
known about the molecular and cellular events that occur down-
stream of epithelial and stromal responses, the unique series of
changes that are imposed on the uterine vasculature before,
during, and after implantation are only known at the level of
morphological description. Here, we show that PR within the
endothelium is responsible for initiating a series of events that
lead to physiological edema in the endometrium. Specifically,
PR induces expression of the orphan nuclear receptor NR4A1,
which in turn destabilizes the endothelial barrier function within
PR-expressing endothelial cells. The consequence is restricted
and sustained vascular permeability directed by circulating P4.
The contribution of P4 as the chief regulator of vascular alter-
ations during the secretory phase was implied by earlier obser-
vations that mice that lacked PR failed to mount a decidual
response (Lydon et al., 1995, 1996). Because expression of PR
in the endothelium was not constitutive, we believed that the
effect on vessels was triggered through the secondary action
of permeability modulators. An obvious culprit, VEGF, has
frequently been suggested to be responsible for the cycle of
vascular changes in the uterus. In fact, VEGF is induced by ste-
roid hormones (Hyder et al., 1996; Shifren et al., 1996; Sugino
et al., 2002) and pharmacological blockade of this growth factor
in primates impairs endothelial repair and angiogenic growth
(Fan et al., 2008). Surprisingly, we found that blockade of
VEGF does not prevent the physiological edema that occurs
prior to implantation; instead, these events appear to be trig-
gered by P4-driven mechanisms that are independent of
VEGF. These findings pointed to either alternative permeability
mediators or a direct role of PR in the endothelium. It should
be noted, however, that inactivation of VEGF signaling postim-
plantation, like P4 blockade, impacts both permeability and
embryo viability. Thus, it appears that themechanisms that regu-
late permeability responses pre- and postimplantation are likely
distinct.
To evaluate the contribution of PR in the vascular endothelium,
we adopted loss- and gain-of-function approaches. Although
mice that lacked PR in the endothelium were able to host the
typical decidual response by stromal cells, they showed an, red). Scale bar, 25 mm.
, red). Arrows indicate endothelial cells withNR4A1 and PR. Scale bar, 20 mm.
ice treated with or without P4. n = 3.
n of control (wild-type) and NR4A1KO mice. ***p < 0.001, ****p < 0.0001. Error
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impaired ability to mount a physiological edema response, with
consequences for implantation. In contrast, transgenic animals
that misexpressed PR on endothelial cells in organs other than
the uterus displayed an acute permeability response upon ligand
exposure. Together, these findings implicated P4 as the medi-
ator of the permeability responses in the uterus.
How does P4 drive vascular permeability? Although the
molecular mechanisms of P4’s action via binding to its receptor
are well established (Edwards et al., 1995; McKenna and
O’Malley, 2000; Rubel et al., 2012), the effects of this hormone
on endothelial cells have not been explored at the molecular
level. An evaluation of the literature on the effect of PR in epithe-
lial cells was not informative as to how this transcription factor
could promote destabilization of barrier function in endothelial
cells. Furthermore, our in vitro experiments indicated that the
effect of PR on endothelial permeability required transcriptional
control. Following that lead, we performed global transcriptional
profiling (RNA-seq) of endothelial cells treated with P4. These
data initially failed to provide insights into the process whereby
PR promotes permeability. It was only by integrating ChIP-seq
analysis with the transcriptional profile that we were able to
identify NR4A1 as the possible link.
The orphan nuclear receptor NR4A1 is a member of the NR4A
transcription factor family, which is expressed by a broad num-
ber of cell types. The effects mediated by NR4A1 are pleiotropic
and cell-type dependent, and impact metabolism, homeostasis,
and inflammation (Pearen and Muscat, 2010; Zhao and Bruem-
mer, 2010). Recently, NR4A1 was also shown to be expressed
by endothelial cells and to induce pathological permeability re-
sponses (Zhao et al., 2011). Reports indicating thatNR4A1 plays
a role in permeability also raised the possibility that this molecule
might be downstream of PR signaling.
A hallmark of vascular leakage is the formation of intercellular
gaps via disruption of cell-cell contacts resulting in a loss of bar-
rier integrity (Dejana et al., 2008; Dvorak, 2010; Komarova and
Malik, 2010). Along these lines, endothelial cells expressing PR
showed disruption of cell-cell interactions upon exposure to
the ligand. Interestingly, silencing of NR4A1 in cells expressing
PR and treated with the ligand blocked the effect of P4 on
permeability. These findings clearly indicated that PR was up-
stream of NR4A1 in the control of endothelial barrier function.
Furthermore, we found thatNR4A1 coordinates an effective pro-
gram of repression of junctional proteins, including VE-cadherin,
claudin-5, and PECAM1.
Our results indicate that under homeostatic conditions, PR
is highly restricted to uterine blood vessels, at the exclusion of
vessels from other organs. Interestingly, expression of PR is
selective to veins and lymphatic vessels. Endothelium from
arteries conspicuously lacks PR, whereas high expression is
noted in the smooth muscle layer of these vessels. This exquisite
specificity enables local and controlled functions to be triggered
by a systemically distributed ligand.
Is PR the only regulator of permeability in the uterus? That is
unlikely, but our findings would indicate that removal of this re-
ceptor from the endothelium significantly impacts permeability
and implantation. This is in sharp contrast to VEGF blockade,
for example, which did not impact embryo viability at preimplan-
tation times. Another important point is that genomic inactivation560 Cell 156, 549–562, January 30, 2014 ª2014 Elsevier Inc.of PR completely blocks permeability. Initially, this finding led us
to speculate that PR might regulate permeability through its
actions in other cell types. However, comparisons between
global and cell-specific PRs are confounded by the global
impact of PR on the differentiation of the uterus. In fact, deletion
of PR from the onset of development impacts the differentiation
of uterine epithelium and stroma, including a reduction in proteo-
glycan levels (Figure S1B) that are critical for interstitial water
retention and contribute to regulation of fluid trafficking in tis-
sues. This might explain why PRKO mice exhibit a much lower
basal content of albumin, while control and PRECKO mice are
equivalent at baseline and only differ upon hormonal treatment.
The findings presented here are in accordancewith and further
explain the uterine vascular fragility experienced by users of
long-term progestin-only contraceptives (Hickey and Fraser,
2002; Kovacs, 1996; Shoupe et al., 1991). In fact, prolonged
exposure to progestins results in abnormal endometrial bleeding
despite increased levels of tissue factor expression (Runic et al.,
2000).
Structural and molecular differences in the endothelium of
distinct tissues reflect its role in meeting the diverse require-
ments of individual organ sites. The recurrent cycles of physio-
logical permeability in the endometrium are unique to this tissue
and must be regulated in a timely manner. Here, we have shown
that this physiological permeability requires a molecular toolkit
distinct from that of pathological permeability. Taken together,
our findings highlight the process by which endothelial cells
detect and respond to systemic hormones to trigger local,
timely, and effective changes in barrier function.
EXPERIMENTAL PROCEDURES
Mouse Models
Details about the mouse models and genotyping used can be found in the
Extended Experimental Procedures. All animals were housed in a pathogen-
free environment in an AAALAC-approved vivarium at UCLA, and experiments
were performed in accordance with the guidelines of the Committee for Animal
Research.
Hormone Treatment
Female tie1-PRTg, PRLacZ, PRECKO, PRKO, and NR4A1KO mice and litter-
mate controls (8–12 weeks old) were treated with hormones as previously
described (Lydon et al., 1995). Details on the hormone treatments can be
found in the Extended Experimental Procedures.
Vascular Permeability Assays
Following hormone treatment,micewere injected intravenously (i.v.) with either
Evans blue dye (Miles assay; 1 ml/kg of 3% Evans blue) or select lectins and
allowed to circulate for 20 min before perfusion fixation (1% paraformalde-
hyde). Select organs were removed, blotted dry, and weighed (wet weight).
Evans blue was extracted from tissues with formamide overnight at 55C and
measured in duplicate by a spectrometer at 620 nm. Details on extraction
and quantification of albumin are provided in the Extended Experimental
Procedures.
Embryo Isolation and Implantation
Embryos were obtained from wild-type females mated with fertile males.
Embryos (2- to 4-cell stage) were recovered by flushing the uteri with Hank’s
balanced salt solution. Twelve embryos were transferred into anesthetized
pseudopregnant females via the infundibulum into the ipsilateral ampulla of
the uterine tube. The peritoneum was sutured and the skin was closed with
a clamp. Counts of implantation sites were performed using a dissecting
microscope (LeicaMicrosystems) and image acquisition and analytic software
(SPOT Imaging Solutions).
Immunohistochemistry
Tissue (5 mm) and/or vibratome (300 mm) sections were immunostained with
antibodies against PR (SP2; Lab Vision), PECAM-1 (MEC 13.1; BD Biosci-
ences), and GFP (Abcam). Antigen retrieval using Tris-EDTA (pH 9.0) was
required for PR staining of formalin-embedded tissues. Alexa Fluor secondary
antibodies were used to recognize primary antibodies (Molecular Probes/Life
Technologies). Sections were analyzed using a Zeiss LSM 510 META multi-
photon microscope with built-in Axiocam and acquired using Zen software
(Zeiss). Details of b-galactosidase staining can be found in the Extended
Experimental Procedures.
Immunoblotting and Immunoprecipitation
Proteins were resolved by SDS-PAGE, transferred to nitrocellulose (BA-S 83;
Optitran), and incubated overnight with antibodies against PR (SP2; Lab
Vision), VE-cadherin (Cell Signaling), PECAM-1 (Cell Signaling), claudin-5
(Invitrogen), b-catenin (Sigma), b-actin (Sigma), pVE-cadherin (pY685 [Orse-
nigo et al., 2012]), FAK (BD Biosciences), b1-integrin (AB1952; Millipore) and
myc (Cell Signaling). Blots were incubated with horseradish peroxidase-conju-
gated secondary antibodies (Bio-Rad Laboratories), developedwith Supersig-
nal West Pico Chemiluminescent Substrate (Thermo Scientific), and imaged
with the use of the Bio-Rad ChemiDoc XRS+ system and accompanying
Image Lab software (Bio-Rad Laboratories). Cell fractionation experiments
were carried out as previously described (Behrmann et al., 2004). Details on
immunoprecipitation can be found in the Extended Experimental Procedures.
ECIS
HUVECs, passages 4–6, were cultured in MCDB-131 (VEC Technologies) with
the addition of 10% fetal bovine serum (Omega Scientific) that was stripped
using 0.25% dextran-coated charcoal (Sigma). PR-infected HUVECS were
seeded onto 8W10E+ arrays and treated with P4 (100 nM) after cells reached
confluence (Applied Biophysics). Data were acquired and analyzed using ECIS
software (Applied Biophysics). For details on the reagents used in the ECIS
experiments, see the Extended Experimental Procedures.
ChIP and Library Preparation
For each condition (negative control, PR+P4, PR only, and IgG control) 10 3
106 and 2 3 106 cultured HUVECs were used per IP for ChIP-seq and
ChIP-qPCR, respectively. HUVECs were infected with a PR lentivirus, grown
to confluence, and then treated with P4 for 1 hr. The library for sequencing
was constructed using the Ovation Ultralow IL Multiplex System 1-8 (Nugen)
according to the manufacturer’s instructions. Libraries were sequenced using
HIseq-2000 (Illumina) to obtain 50 bp long reads. The ChIP-seq data sets have
been deposited in the National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus (GEO) under accession number GSE43786. For
details on ChIP and how peaks were called and analyzed, see the Extended
Experimental Procedures.
RNA Isolation, qPCR, and Library Preparation
Total RNA was extracted from organs and cells using the RNeasy Kit
(QIAGEN), cDNA generated using the SuperScript First-strand Synthesis
System (Invitrogen), and real-time qPCR was performed using SYBR Green
reagent (QIAGEN) and detected using an Opticon2 PCR machine (MJ
Research; BioRad). The library for sequencing was constructed using the Illu-
mina Multiplex System (Illumina) according to the manufacturer’s instructions.
Libraries were sequenced using HIseq-2000 (Illumina) to obtain 50-bp-long
reads. The RNA-seq data sets have been deposited in the NCBI GEO
under accession number GSE46502. For details on how differentially ex-
pressed genes were identified and analyzed see the Extended Experimental
Procedures.
Statistical Analysis
For statistical analysis, Student’s unpaired two-tailed t test was used for all
comparisons.ACCESSION NUMBERS
The ChIP-seq and RNA-seq data sets have been deposited in the NCBI GEO
under accession numbers GSE43786 and GSE46502, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2013.12.025.
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